January 26, 2015 8:36 PM ET


Company Overview of Acetylon Pharmaceuticals, Inc.

Company Overview

Acetylon Pharmaceuticals, Inc. discovers and develops selective small molecule histone deacetylase inhibitors and other targeted drugs for the treatment of cancers, inflammatory, neurodegenerative, genetic, and infectious diseases. It has a strategic partnership with Celgene Corporation. The company was founded in 2008 and is based in Boston, Massachusetts.

70 Fargo Street

Suite 205

Boston, MA 02210

United States

Founded in 2008





Key Executives for Acetylon Pharmaceuticals, Inc.

Chief Executive Officer
Age: 57
Co-Founder and Chairman of the Board
Age: 51
Scientific Founder
Scientific Founder and Member of the Advisory Board
Scientific Founder
Age: 63
Compensation as of Fiscal Year 2014.

Acetylon Pharmaceuticals, Inc. Key Developments

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM

Acetylon Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 01:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Walter C. Ogier, Chief Executive Officer, President and Director.

Acetylon Pharmaceuticals, Inc. Announces Phase 1b Combination Studies in Multiple Myeloma

Acetylon Pharmaceuticals, Inc. announced positive data from two ongoing Phase 1b combination clinical trials of ricolinostat, a selective HDAC6 inhibitor, for the treatment of relapsed or refractory multiple myeloma. In both studies, ricolinostat continues to demonstrate a favorable safety profile and substantial disease response rates. For ricolinostat in combination with lenalidomide (Revlimid®) and dexamethasone, the most common treatment emergent adverse events (AEs) were fatigue, upper respiratory infection, anemia, neutropenia, diarrhea, nausea, thrombocytopenia, muscle spasms, dizziness and rash as well as asymptomatic laboratory abnormalities. In combination with lenalidomide and dexamethasone, ricolinostat demonstrated an overall response rate of 64%, with of 80% of patients achieving minimal response or better, per modified International Myeloma Working Group (IMWG) criteria. The response rate in 21 relapsed, lenalidomide refractory patients was 50%, whereas the response rate in 13 non-refractory patients was 85%. These responses were durable, with patients remaining on therapy up to 23+ cycles of therapy. The most common AEs for ricolinostat in combination with bortezomib (Velcade®) and dexamethasone were diarrhea, increased creatinine, fatigue, anemia, nausea and thrombocytopenia that were predominantly grade 1-2. Diarrhea was the only AE that increased with higher ricolinostat exposure. Grade 3-4 thrombocytopenia was seen in 42% of patients. In combination with bortezomib and dexamethasone, ricolinostat demonstrated an overall response rate of 45% in disease evaluable patients and 30% in all patients, with 31% of all patients enrolled achieving minimal response or better (per modified IMWG criteria). The data were presented at the 56thAmerican Society of Hematology (ASH) Annual Meeting in San Francisco, California. Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM) (poster presentation, Abstract #4764): Of 43 patients, 3 achieved VGPR, 10 achieved PR, 2 achieved MR, 10 achieved SD and 4 had progressive disease, per modified IMWG criteria (Rajkumar, Blood 2011). 27 of 43 patients were refractory to bortezomib; within these patients, a 29 % overall response rate was achieved in response evaluable patients (4 of 14), and in 15% of all refractory patients entered on study. Treatment emergent adverse events (AEs) were predominantly grade 1-2. The most common AEs were diarrhea, thrombocytopenia, increased creatinine, fatigue, nausea, throat irritation, electrolyte abnormalities, cough, anemia, decreased appetite, peripheral neuropathy, peripheral edema, upper respiratory tract infection, dizziness, fever and vomiting. Thrombocytopenia and anemia were the most common grade 3 and 4 adverse events. Although there was no difference in the grade or frequency of overall AEs when ricolinostat dosing was increased to twice daily, diarrhea occurred earlier in the course of treatment and there was an increase in the frequency of serious adverse events.

Acetylon Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 02:00 PM

Acetylon Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-23-2014 02:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Similar Private Companies By Industry

Company Name Region
Rapa Holdings Inc. United States
Teva Pharmaceuticals USA, Inc. United States
Bodyonics Ltd. United States
Ancora Pharmaceuticals, Inc. United States
Entropin Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Acetylon Pharmaceuticals, Inc., please visit www.acetylon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.